TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008;47:503-9. 7.263 Rapidis AD. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: perspectives from a maxillofacial surgeon. Clin Microbiol Infect 2008;15(suppl. 1):98-102. 7.264 Cornely OA et al. Current experience in treating invasive zygomycosis with posaconazole. Clin Micro-biol Infect 2009;15(suppl. 1):77-81. 7.265 van Burik JA et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 93 cases. Clin Infect Dis 2006;42:e61-5. 7.266 Keating GM. Posaconazole. Drugs 2005;65:1553-67. 7.267 Greenberg RN et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126-33. 7.268 Reed C et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008;47:364-71. 7.269 Tragiannidis A et al. Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis. Clin Microbiol Infect 2009;15(suppl. 1):82-6. 7.270 Mastroianni A. Paranasal sinus mucormycosis in an immunocompetent host: efficacy and safety of combination therapy with liposomal amphotericin B and adjuvant rHuGM-CSF. Infez Med 2004;4: 278-83. 7.271 Spellberg B et al. Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep 2010,12: 423-9. 7.272 Pang KR et al. Subcutaneous fungal infections. Dermatol Ther 2004;17:523-31. 7.273 Garnica M et al. Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, phaehyphomycosis and chromoblastomycosis. Curr Opin Infect Dis 2009;22:559-63. 7.274 Ahmed AO et al. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet Infect Dis 2004;4:566-74. 7.275 Ramos-e-Silva M et al. Paracoccidioidomycosis. Dermatol Clin 2008;26:257-69. 7.276 Travassos LR et al. Treatment options for paracoccidioidomycosis and new strategies investigated. Expert Rev Anti Infect Ther 2008;6:251-62. 7.277 Pang KR et al. Subcutaneous fungal infections. Dermatol Ther 2004;17:523-31. 7.278 Vanittanakom N et al. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev 2006;19:95-110. 7.279 Sirisanthana T et al. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus infected patients. Clin Infect Dis 1998;26:1107-10. 7.280 Sirisanthana T et al. Epidemiology and management of penicilliosis in human immunodeficiency virus infected patients. Int J Infect Dis 1998;3:48-53. 7.281 Ustianowski AP et al. Penicillium marneffei infection in HIV. Curr Opin Infect Dis 2008;21:31-6. 7.282 Pastor FJ et al. Alternaria infections: laboratory diagnosis and relevant clinical features. Clin Microbiol Infect 2008;14:734-46. 7.283 Steinbach WJ et al. Scedosporium species infections and treatments. J Chemother 2003;15(suppl. 2):16-27. 7.284 Pang KR et al. Subcutaneous fungal infections. Dermatol Ther 2004;17:523-31. 7.285 Revankar SG et al. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002;34:467-76. 7.286 Pfaller MA et al. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43 (suppl. 1):S3-14. 7.287 Ben-Ami R et al. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis 2009;48:1033- 41. 7.288 Revankar SG. Phaeohyphomycosis. Infect Dis Clin North Am 2006;20:609-20. 7.289 Li DM et al. Cerebral phaeohyphomycosis – a cure at what lengths? Lancet Infect Dis 2009;9:376- 83. 7.290 Bhat SV et al. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis 2007;39: 87-90. 7.291 Revankar SG et al. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis 2004;38:206-16. 7.292 Perfect JR et al. Voriconazole treatment for less common, emerging or refractory fungal infections. Clin Infect Dis 2003;36:1122-31. 7.293 Troke P et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008;52:1743-50. 7.294 Garnica M et al. Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, phaehyphomycosis and chromoblastomycosis. Curr Opin Infect Dis 2009;22:559-63. 7.295 Stringer JR et al. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002;8:891-6. 7.296 Calderón EJ et al. Pneumocystis infections in humans: diagnosis and treatment. Expert Rev Anti Infect Ther 2010;8:683-701. 7.297 Tasaka S et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest 2007;131: 1173-80. 7.298 Walzer PD et al. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis 2008;46:625-33. 7.299 Morris A. Is there anything new in Pneumocystis jirovecii pneumonia? Changes in P. jirovecii pneumonia over the course of the AIDS epidemic. Clin Infect Dis 2008;46:634-6. 7.300 Thomas CF et al. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-98. 7.301 Kovacs JA et al. New insights into transmission, diagnosis and drug treatment of Pneumocystis carinii pneumonia. J Am Med Assoc 2001;286:2450-60. 7.302 Kovacs JA et al. Evolving health effects of Pneumocystis. One hundred years of progress in diagnosis and treatment. J Am Med Assoc 2009;301:2578-85. 7.303 Benfield T et al. Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia. A case series and systematic review. J Acquir Immune Defic Syndr 2008;48:63-7. 7.304 Cortez KJ et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008;21:157-97. 7.305 Lamaris GA et al. Scedosporium infection in a tertiary care cancer center: a review of 25 cases 1989-
2006. Clin Infect Dis 2006;43:1580-4. 7.306 O‘Bryan TA. Pseudallescheriasis in the 21 st century. Expert Rev Anti Infect Ther 2005;3:765-73. 7.307 Castiglioni B et al. Pseudallescheria boydii (anamorph Scedosporium apiospermum) infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine 2002;81: 333-48. 7.308 Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001;39:954-8. 7.309 Carrillo AJ et al. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001;45:2151-3. 7.310 Walsh TJ et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21:240-8. 7.311 Fortún J et al. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis 2003;22:408-13. 7.312 Kauffman CA et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007;45:1255-65. 7.313 Kauffman CA. Endemic mycoses: blastomycosis, histoplasmosis, and sporotrichosis. Infect Dis Clin North Am 2006;20:645-62. 7.314 Bustamante B et al. Sporotrochosis: a forgotten disease in the drug research agenda. Expert Rev Anti Infect Ther 2004;2:85-94. 7.315 Pang KR et al. Subcutaneous fungal infections. Dermatol Ther 2004;17:523-31. 7.316 Queiroz-Telles F et al. Subcutaneous mycoses. Infect Dis Clin North Am 2003;17:59-85. 7.317 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Morb Mortal Wkly Rep 2009;58(RR-4):1- 207. 7.318 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. Morb Mortal Wkly Rep 2009; 58(RR-11):1-167. 8.1 de la Cámara R. Antifungal prophylaxis in haematology patients. Clin Microbiol Infect 2006; 12(suppl. 7):65-76. 8.2 Segal BH et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of new broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007;44:402-9. 8.3 Hwang YY et al. Antifungal prophylaxis and treatment in patients with hematological malignancies. Expert Rev Anti Infect Ther 2010;8:397-404. 8.4 Sipsas NV et al. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis 2006;42:1584-91. 8.5 Hughes WT et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51. 8.6 Singh N et al. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005;18:44-69. 8.7 de la Cámara R. Antifungal prophylaxis in haematology patients. Clin Microbiol Infect 2006;12 (suppl. 7):65-76. 8.8 Segal BH et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of new broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007;44:402-9. 8.9 Hwang YY et al. Antifungal prophylaxis and treatment in patients with hematological malignancies. Expert Rev Anti Infect Ther 2010;8:397-404. 8.10 Hughes WT et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51. 8.11 de la Cámara R. Antifungal prophylaxis in haematology patients. Clin Microbiol Infect 2006;12 (suppl. 7):65-76. 8.12 Segal BH et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of new broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007;44:402-9. 8.13 Hwang YY et al. Antifungal prophylaxis and treatment in patients with hematological malignancies. Expert Rev Anti Infect Ther 2010;8:397-404. 8.14 Hughes WT et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51. 8.15 Rotstein C et al. Randomized, placebo controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999;28: 331-40. 8.16 Menichetti F et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo controlled, double blind, multicenter trial. Clin Infect Dis 1999;28:250-5. 8.17 Powderly WG et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-5. 8.18 Powderly WG et al. Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. AIDS Res Hum Retroviruses 1999;15:1619-23. 8.19 Saag MS et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS associated cryptococcal meningitis. Clin Infect Dis 1999;28:291-6. 8.20 McKinsey DS et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. Clin Infect Dis 1999;28:1049-56. 8.21 Wheat J et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993;118:610-6. 8.22 de la Cámara R. Antifungal prophylaxis in haematology patients. Clin Microbiol Infect 2006;12 (suppl. 7):65-76. 8.23 Segal BH et al. Prevention and early treatment of invasive fungal infection in patients with cancer and
Page 1 and 2: TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4: 1.89 Laupland KB. Vascular and para
Page 5 and 6: of NICE guidance. Br Med J 2008;337
Page 7 and 8: tions à Clostridium difficile dans
Page 9 and 10: sis of placebo-controlled trials. C
Page 11 and 12: 1.446 Centers for Disease Control a
Page 13 and 14: 1.532 Olaison L et al. Enterococcal
Page 15 and 16: 1.615 Muder RR et al. Isolation of
Page 17 and 18: 2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20: 2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22: 1.873 Korting HC et al. Current top
Page 23 and 24: 1.970 Thomas RJ et al. Current mana
Page 25 and 26: of severe respiratory failure. Clin
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51: nail onychomycosis. J Eur Acad Derm
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77 and 78: tients. J Antimicrob Chemother 2009
Page 79 and 80: duct characteristics. Available at:
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86: North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88: 1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90: 21.358 Calabrese LH et al. Viral Ar
Page 91 and 92: 24. 21.452 Jeha LE et al. Long term
Page 93 and 94: induced functional androgen deficie
Page 95 and 96: 25A.27 Conseil Supérieur de la San
Page 97 and 98: product characteristics. Available
Page 99 and 100: mortality after kidney transplantat
Page 101 and 102: 33A.1 Kearney BP et al. The penetra
Page 103 and 104:
Clin Plast Surg Clinics in Plastic
Page 105 and 106:
Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

Create successful ePaper yourself

Delete template?

Save as template?